150 related articles for article (PubMed ID: 33573542)
1. Quinoxaline 1,4-di-N-Oxide Derivatives: Are They Unselective or Selective Inhibitors?
Rivera G
Mini Rev Med Chem; 2022; 22(1):15-25. PubMed ID: 33573542
[TBL] [Abstract][Full Text] [Related]
2. Quinoxaline Moiety: A Potential Scaffold against
Montana M; Montero V; Khoumeri O; Vanelle P
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443334
[No Abstract] [Full Text] [Related]
3. Quinoxaline and quinoxaline-1,4-di-N-oxides: An emerging class of antimycobacterials.
Keri RS; Pandule SS; Budagumpi S; Nagaraja BM
Arch Pharm (Weinheim); 2018 May; 351(5):e1700325. PubMed ID: 29611626
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of quinoxaline-2-carboxylate 1,4-di-N-oxide derivatives in experimental tuberculosis.
Vicente E; Villar R; Burguete A; Solano B; Pérez-Silanes S; Aldana I; Maddry JA; Lenaerts AJ; Franzblau SG; Cho SH; Monge A; Goldman RC
Antimicrob Agents Chemother; 2008 Sep; 52(9):3321-6. PubMed ID: 18625764
[TBL] [Abstract][Full Text] [Related]
5. Current status of quinoxaline and quinoxaline 1,4-di-N-oxides derivatives as potential antiparasitic agents.
Soto-Sánchez J; Ospina-Villa JD
Chem Biol Drug Des; 2021 Oct; 98(4):683-699. PubMed ID: 34289242
[TBL] [Abstract][Full Text] [Related]
6. Anti-Trypanosoma cruzi and anti-leishmanial activity by quinoxaline-7-carboxylate 1,4-di-N-oxide derivatives.
Villalobos-Rocha JC; Sánchez-Torres L; Nogueda-Torres B; Segura-Cabrera A; García-Pérez CA; Bocanegra-García V; Palos I; Monge A; Rivera G
Parasitol Res; 2014 Jun; 113(6):2027-35. PubMed ID: 24691716
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, 3D-QSAR analysis and biological evaluation of quinoxaline 1,4-di-N-oxide derivatives as antituberculosis agents.
Pan Y; Li P; Xie S; Tao Y; Chen D; Dai M; Hao H; Huang L; Wang Y; Wang L; Liu Z; Yuan Z
Bioorg Med Chem Lett; 2016 Aug; 26(16):4146-53. PubMed ID: 27426298
[TBL] [Abstract][Full Text] [Related]
8. Anti-
Palos I; Luna-Herrera J; Lara-Ramírez EE; Loera-Piedra A; Fernández-Ramírez E; Aguilera-Arreola MG; Paz-González AD; Monge A; Wan B; Franzblau S; Rivera G
Molecules; 2018 Jun; 23(6):. PubMed ID: 29914062
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in design of potential quinoxaline anti-infectives.
Jampilek J
Curr Med Chem; 2014; 21(38):4347-73. PubMed ID: 25312209
[TBL] [Abstract][Full Text] [Related]
10. New hydrazine and hydrazide quinoxaline 1,4-di-N-oxide derivatives: In silico ADMET, antiplasmodial and antileishmanial activity.
Quiliano M; Pabón A; Ramirez-Calderon G; Barea C; Deharo E; Galiano S; Aldana I
Bioorg Med Chem Lett; 2017 Apr; 27(8):1820-1825. PubMed ID: 28291694
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo antimycobacterial activities of ketone and amide derivatives of quinoxaline 1,4-di-N-oxide.
Villar R; Vicente E; Solano B; Pérez-Silanes S; Aldana I; Maddry JA; Lenaerts AJ; Franzblau SG; Cho SH; Monge A; Goldman RC
J Antimicrob Chemother; 2008 Sep; 62(3):547-54. PubMed ID: 18502817
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and antimycobacterial activity of new quinoxaline-2-carboxamide 1,4-di-N-oxide derivatives.
Moreno E; Ancizu S; Pérez-Silanes S; Torres E; Aldana I; Monge A
Eur J Med Chem; 2010 Oct; 45(10):4418-26. PubMed ID: 20656380
[TBL] [Abstract][Full Text] [Related]
13. Anti-Mycobacterium tuberculosis agents derived from quinoxaline-2-carbonitrile and quinoxaline-2-carbonitrile 1,4-di-N-oxide.
Ortega MA; Sainz Y; Montoya ME; Jaso A; Zarranz B; Aldana I; Monge A
Arzneimittelforschung; 2002; 52(2):113-9. PubMed ID: 11878199
[TBL] [Abstract][Full Text] [Related]
14. New quinoxaline 1,4-di-N-oxides. Part 1: Hypoxia-selective cytotoxins and anticancer agents derived from quinoxaline 1,4-di-N-oxides.
Amin KM; Ismail MM; Noaman E; Soliman DH; Ammar YA
Bioorg Med Chem; 2006 Oct; 14(20):6917-23. PubMed ID: 16843668
[TBL] [Abstract][Full Text] [Related]
15. QSAR analysis for quinoxaline-2-carboxylate 1,4-di-N-oxides as anti-mycobacterial agents.
Vicente E; Duchowicz PR; Castro EA; Monge A
J Mol Graph Model; 2009 Aug; 28(1):28-36. PubMed ID: 19394254
[TBL] [Abstract][Full Text] [Related]
16. An appraisal on synthetic and pharmaceutical perspectives of quinoxaline 1,4-di-N-oxide scaffold.
Agrawal N; Bhardwaj A
Chem Biol Drug Des; 2022 Sep; 100(3):346-363. PubMed ID: 35610776
[TBL] [Abstract][Full Text] [Related]
17. Selective activity against Mycobacteriumtuberculosis of new quinoxaline 1,4-di-N-oxides.
Vicente E; Pérez-Silanes S; Lima LM; Ancizu S; Burguete A; Solano B; Villar R; Aldana I; Monge A
Bioorg Med Chem; 2009 Jan; 17(1):385-9. PubMed ID: 19058970
[TBL] [Abstract][Full Text] [Related]
18. Trypanocidal Activity of Quinoxaline 1,4 Di-N-oxide Derivatives as Trypanothione Reductase Inhibitors.
Chacón-Vargas KF; Nogueda-Torres B; Sánchez-Torres LE; Suarez-Contreras E; Villalobos-Rocha JC; Torres-Martinez Y; Lara-Ramirez EE; Fiorani G; Krauth-Siegel RL; Bolognesi ML; Monge A; Rivera G
Molecules; 2017 Feb; 22(2):. PubMed ID: 28157150
[TBL] [Abstract][Full Text] [Related]
19. Novel quinoxaline 1,4-di-N-oxide derivatives as new potential antichagasic agents.
Torres E; Moreno-Viguri E; Galiano S; Devarapally G; Crawford PW; Azqueta A; Arbillaga L; Varela J; Birriel E; Di Maio R; Cerecetto H; González M; Aldana I; Monge A; Pérez-Silanes S
Eur J Med Chem; 2013 Aug; 66():324-34. PubMed ID: 23811257
[TBL] [Abstract][Full Text] [Related]
20. Mutagenicity of quindoxin, its metabolites, and two substituted quinoxaline-di-N-oxides.
Beutin L; Preller E; Kowalski B
Antimicrob Agents Chemother; 1981 Sep; 20(3):336-43. PubMed ID: 7030199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
